Inside GRAPPA

In this episode, host Dr. Fabian Proft explores the most impactful research and updates from the EADV 2024 Congress in Amsterdam. Joining him are distinguished Young GRAPPA members Dr. Dimitri Luz, Dr. Ahmet Uğur, and Dr. Margo Gkini, who each share their expert perspectives on groundbreaking studies and their implications for psoriatic disease care.Episode Highlights:What the latest research reveals about psoriasis pathophysiology.  How biologics are impacting long-term treatment safety and efficacy.  Insights into the gut-skin connection and its role in inflammation.Resources and Links:  Learn more about GRAPPA: GRAPPA Official Website  Discover highlights from the GRAPPA EADV 2024 Congress Highlights.🎧 Subscribe to Inside GRAPPA on your favorite podcast platform for more updates on cutting-edge research and clinical strategies in psoriasis and psoriatic arthritis. Don't miss the next episode---stay tuned and stay curious! Hosted on Acast. See acast.com/privacy for more information.

How should musculoskeletal symptoms in psoriasis patients be managed---and who should take the lead? In this episode of Inside GRAPPA, Dr. Mio Nakamura moderates a compelling debate featuring Dr. Laura Savage, Consultant Dermatologist from Leeds Teaching Hospital, UK, and Dr. Fabian Proft, Rheumatologist from Berlin, Germany. Together, they tackle the vital question: Should dermatologists or rheumatologists be in the driver's seat when managing psoriatic arthritis (PsA)?Listen as they discuss:  The role of dermatologists in early detection and PsA prevention.    Rheumatologists' emphasis on precise diagnosis and targeted treatment.    The power of collaborative care in improving patient outcomes.Join us for an engaging conversation about the challenges and opportunities in PsA management, and how multidisciplinary approaches can lead to better care for patients with psoriatic disease.Featured Guests  Dr. Laura Savage: Consultant Dermatologist specializing in psoriatic disease, advocating for early intervention strategies in dermatology.    Dr. Fabian Proft: Rheumatologist with expertise in imaging and precision medicine for inflammatory arthritis.Resources & Links  Discover GRAPPA's commitment to collaboration: GRAPPA Website.    Catch up on past episodes of Inside GRAPPA: Podcast Archive.🎙️ Don't miss this episode filled with expert perspectives on psoriatic disease care. Subscribe to Inside GRAPPA and be part of the conversation! Hosted on Acast. See acast.com/privacy for more information.

Today on Inside GRAPPA, host Sebastian Herrera is joined by Lourdes Perez Chada, an Instructor in Dermatology at Harvard Medical School and a clinical investigator at the Brigham and Women’s Hospital in Boston, and Cheryl Rosen who is the Head of the Division of Dermatology,Toronto Western Hospital and University Health Network Hospitals, a Clinician Investigator at Toronto Western Hospital, and a Professor of the Dept of Medicine, University of Toronto.In this episode, we discuss the importance of nail psoriasis, including the prevalence, manifestations, and diagnosis, and how it affects patients in their daily lives.Key Topics:Prevalence and Diagnosis: Nail psoriasis affects about 50% of patients with psoriasis and up to 90% over their lifetime. The experts discuss clinical diagnostic methods and the challenges in identifying the condition. Tools like biopsies and imaging are rarely used due to their invasiveness.Differential Diagnosis: They examine common conditions that can be mistaken for nail psoriasis, including onychomycosis (fungal infections), lichen planus, and alopecia areata.Impact on Quality of Life: Nail psoriasis has a significant impact, especially in terms of physical pain, mental health, and daily activities. Patients may experience anxiety and depression, particularly when their hands or feet are affected.Association with Psoriatic Arthritis: Nail psoriasis is a risk factor for developing psoriatic arthritis, due to the anatomical connection between the nail and underlying bones. The discussion covers how this link affects prognosis and treatment.Treatment Options: Historically difficult to treat, nail psoriasis management ranges from doing nothing for mild cases to topical treatments and biologics. The experts focus on biologics like Ixekizumab and Tofacitinib (Xeljanz), which have shown promise in treating both nail disease and psoriatic arthritis.Stay Connected For more intriguing insights and episodes, visit our website. Don't forget to subscribe to Inside GRAPPA for more episodes like this. Share with your colleagues and friends who might benefit from this episode! Hosted on Acast. See acast.com/privacy for more information.

Today on Inside GRAPPA, host Fabian Proft is joined by Professor Elaine Husni and Professor Stefan Siebert to discuss the management of conditions related to psoriatic arthritis (PSA), particularly inflammatory bowel disease (IBD) and uveitis. In this episode, we discuss treatment modalities, the importance of early diagnosis, and the implications for clinical practice. The experts also delve into future directions for PSA treatment, highlighting the evolving field of biologics and interdisciplinary approaches. This episode offers a comprehensive exploration of managing associated conditions in PSA, emphasizing the importance of personalized treatment strategies.What's inside this episode?Understanding Psoriatic Arthritis: Insights into managing associated conditions like IBD and uveitis.Expert Discussions: Professors Husni and Siebert share their experiences and approaches in treating these complex cases.Future of Treatment: An overview of emerging therapies and the importance of interdisciplinary collaboration in PSA management.Clinical Perspectives: Exploring the impact of early diagnosis and treatment personalization on patient outcomes.Stay Connected For more intriguing insights and episodes, visit our website. Don't forget to subscribe to Inside GRAPPA for more episodes like this. Share with your colleagues and friends who might benefit from this episode! Hosted on Acast. See acast.com/privacy for more information.

Explore the realm of enthesitis and its treatment advancements in this informative episode of Inside GRAPPA. With renowned experts, Philip Mease (USA) and Dr. Lihi Eder (Canada), we journey through the intricacies of these diseases, emphasizing the manuscript "Management of Enthesitis in Patients with Psoriatic Arthritis." Discover the essence of Enthesitis, the challenges in its diagnosis, and the promising horizon of treatments. Stay curious as we unravel the complexities of this intriguing topic together!Key Highlights:Manuscript Spotlight:  "Management of Enthesitis in Patients with Psoriatic Arthritis" - A comprehensive paper spotlighting the advancements and current insights on psoriatic arthritis and enthesitis.Understanding Enthesitis: The essence and impact of Enthesitis in the medical landscape. The diagnostic challenges and the role of ultrasound in offering a game-changing solution.Journey through Treatments:Historical insights into enthesitis and the tools, like the Leeds Enthesitis Index and SPARC, that have transformed our understanding over the last 25 years.The evolution of treatments, what the present offers, and a sneak peek into the future of psoriatic arthritis treatment.Unveiling the Future: The burning questions surrounding the pathophysiology of Enthesitis and the unmet needs in its management. The promising direction of current research and what it aims to achieve.Resources and Links: Manuscript: Management of Enthesitis in Patients with Psoriatic Arthritis. Organizations: CorEvitas Cohort - Delve deeper into the studies that shape our understanding of enthesitis. Hosted on Acast. See acast.com/privacy for more information.

In this enlightening episode of Inside GRAPPA, we delve deep into the intricate world of peripheral arthritis in psoriatic disease. Today's host, Dr. Sebastian Herrera, is joined by the esteemed Dr. Katy Leung, and Professor Oliver Fitzgerald to discuss the significance, manifestation, and management of peripheral arthritis in patients with psoriatic disease.Dr. Herrera is a rheumatologist at Clínica Las Américas Auna and ARTMEDICA in Medellín, Colombia and also an Associate Professor of Rheumatology at Universidad CES and a member of Young GRAPPA. Dr. Leung is an Associate Professor at Singapore General Hospital and Duke-NUS Medical School in Singapore. Dr. Leung has interest in clinical and translational research in PsA, is the co-chair of the GRAPPA-OMERACT Outcome Measure Working group, and is also a member of the GRAPPA Education Committee. Dr. Fitzgerald is based at University College Dublin and has a major interest in clinical and translational research in PsA. More recent studies have explored genetic factors and biomarker development. Dr. Fitzgerald has been involved for many years with GRAPPA and took up the office of co-President in July 2021. He has been advocating for grant application opportunities addressing critical unmet needs in PsA for some time and this has culminated in the award of the first, significant, joint EU/industry funded Innovative Medicines Initiative (IMI) grant in PsA, the HIPPOCRATES consortium.🗝 Key Points & Highlights:   - Importance of Peripheral Arthritis:A critical manifestation in psoriatic disease, contributing to morbidity and irreversible joint damage if uncontrolled.Early detection and treatment are paramount to prevent long-term disability.   - Symptoms and Manifestations:Peripheral arthritis often presents as the first sign, leading to joint pain, swelling, and Arthralgia.Studies highlight its prevalence, with erosions noted in 47% of patients within two years of symptom onset.   - Risk Factors and Associations:Family history of psoriatic arthritis, severity of psoriasis, and obesity are common risk factors.The presence of certain genetic markers and clinical features can help predict the development of psoriatic arthritis.   - Treatment Strategies & Recommendations:The episode discusses the use of conventional DMARDs like methotrexate and the divergence in treatment preferences across continents.TNF blockers, IL-17 blockers, IL-23 blockers, and JAK inhibitors are strongly recommended, highlighting the need for more head-to-head studies to guide treatment choices.📚 Resources and Studies Mentioned:TICOPA trial & PSA SIM trial: Examining the efficacy of conventional DMARDs in peripheral arthritis.Presto Study: Investigating predictive factors for the onset of psoriatic arthritis.Hippocrates Consortium: Conducting extensive research on various treatments focusing on methotrexate, TNF inhibitors, and JAK inhibitors.🔗 Links and Social Media:Visit our Website for more information.Follow us on YouTube, Facebook, and Twitter. Hosted on Acast. See acast.com/privacy for more information.

Welcome to Inside GRAPPA, a podcast and brought to you by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Our mission is to enhance understanding and treatment of psoriasis and psoriatic arthritis through the sharing of research, knowledge, and collaborative efforts​.We bring together leading rheumatologists, dermatologists, scientists, patient representatives, and industry partners, uniting our passions to make a difference for those living with these conditions​.Join our host Fabian Proft as we navigate the challenges, share the latest research, and explore the triumphs in the world of psoriasis and psoriatic arthritis. Together, we can make a difference. Hosted on Acast. See acast.com/privacy for more information.